News

Codexis to Present Innovations in RNA Therapies at Conference

Codexis to Present Innovations in RNA Therapies at Conference

Codexis to Participate in Enzymatic Synthesis Presentations

Codexis, Inc. (NASDAQ: CDXS), a frontrunner in enzyme engineering, has announced its participation in the upcoming RNA Leaders annual meeting. This event will highlight innovative strategies for manufacturing short inhibitory ribonucleic acid (siRNA) duplexes.

Keynote Presentation Details

During a keynote panel, Stefan Lutz, PhD, the Senior Vice President of Research at Codexis, will join other prominent figures in the RNA industry to discuss advancements in RNA manufacturing processes and strategies aimed at improving production capabilities.

Focus on Ligation for siRNA Manufacturing

Codexis will also showcase ligation techniques that facilitate the efficient synthesis of siRNA duplexes. This presentation will emphasize cost reductions achieved through short fragment synthesis, highlighting the company's state-of-the-art enzyme technology and optimization services designed to enhance performance and scalability in manufacturing.

About RNAi Therapeutics Manufacturing

Ribonucleic acid (RNA) has become a vital therapeutic option, especially with the increasing prominence of mRNA vaccines and siRNA candidates. However, traditional manufacturing methods encounter challenges related to quality control and scalability. With over 450 RNAi therapies currently in development, Codexis is committed to addressing the growing demand by refining its production techniques.

Introducing the ECO Synthesis™ Manufacturing Platform

To enhance the scalability and cost-effectiveness of RNAi therapeutics, Codexis has developed the Enzyme Catalyzed Oligonucleotide (ECO) Synthesis™ platform. Recent presentations have demonstrated successful enzymatic synthesis processes that achieve higher purity and efficiency compared to conventional methods.

About Codexis

Codexis specializes in enzyme engineering, leveraging its proprietary technology to create high-performance enzymes that tackle challenges in pharmaceuticals and nucleic acid synthesis. The company's dedication to innovation fosters greater efficiency, reduced waste, and improved manufacturing practices.

Frequently Asked Questions

What is the focus of Codexis' presentations?

Codexis will concentrate on enzyme-driven methods to enhance siRNA manufacturing, showcasing their innovations at the RNA Leaders meeting.

Who will represent Codexis at the conference?

Stefan Lutz, PhD, and Mathew Miller, PhD, will present advancements in RNA manufacturing and the ECO Synthesis™ platform, respectively.

What challenges does RNA manufacturing face today?

Current RNA manufacturing methods grapple with issues of quality control, scalability, and economic efficiency, especially as the demand for RNA therapeutics continues to grow.

What is the ECO Synthesis™ platform?

The ECO Synthesis™ platform is Codexis' proprietary technology aimed at enabling scalable and cost-effective production of RNA therapeutics through enzymatic processes.

How does Codexis contribute to the field of pharmaceuticals?

Codexis enhances pharmaceutical manufacturing by providing innovative enzyme solutions that improve yields, minimize waste, and advance nucleic acid synthesis.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

PAG, HOWL and PSNL Deals Face Fresh Shareholder Checks

Updated Category News Views 60

Three proposed takeovers, three very different headaches, and one familiar question that never gets old: are regular shareholders actually receiving the best available deal? On Nov. 20, 2026, investor-rights law firm Halper Sadeh LLC said it was investigating the proposed transactions involving Penske Automotive Group, Werewolf Therapeutics and Personalis for potential...

Continue Reading
Birla Carbon's Rayong Bet Tightens Asian Supply Lines

Updated Category News Views 130

Rayong just became a much louder pin on Asia's industrial map. Birla Carbon has inaugurated a 120 kMT carbon black plant in Thailand, and the significance is bigger than a ribbon-cutting photo. This is a capacity-and-location move aimed squarely at the uncomfortable part of industrial supply chains: customers need material when they need it, not after it has spent weeks...

Continue Reading
Trip.Best Expands Global Travel Discovery Footprint

Updated Category News Views 123

Sydney just became the map pin for a fairly serious travel-content land grab. Trip.Best, Trip.com Group's ranking brand, has rolled out its 2027 Annual Rankings with coverage of all seven continents for the first time. This is not an earnings release, and nobody should pretend a hotel list magically turns into revenue by lunchtime. Still, the jump from 85 to 98 annual...

Continue Reading
Mimic Bets Virtual Patching Can Calm AI Patch Chaos

Updated Category News Views 119

Three ugly outages in four days can make even hardened technology buyers reconsider the sacred ritual of “patch immediately.” Mimic’s new Virtual Patching offering arrives squarely in that uncomfortable gap: a vulnerability is known, attackers may be moving fast, and the proper vendor update still needs testing before somebody detonates production. The company’s...

Continue Reading
Veterinary Biologics Growth Has a Valuable Catch Ahead

Updated Category News Views 55

Pet allergies and livestock disease are hardly glamorous, yet they are becoming a durable spending lane. The veterinary biologics market is projected to rise from $2.85 billion in 2026 to $3.69 billion by 2031, a 5.3% compound annual growth rate. That is not the kind of growth figure that makes anyone pound the table, and frankly it should not. It is the sort that can...

Continue Reading
Label-Free Detection Has a Solid, Narrow Growth Lane

Updated Category News Views 77

Biologics labs are turning into a far better hunting ground for analytical equipment than the old, broad-brush research story suggests. Label-free detection is not a giant market, and nobody should dress it up as one. But the projected move from $0.58 billion in 2026 to $0.85 billion by 2031 points to a useful 8.1% annual growth lane, driven by work researchers genuinely...

Continue Reading
FFR Adds Academic and Commercial Muscle to Its Board

Updated Category News Views 65

Robotics boards can get crowded with lofty nouns fast, and FFR just added another one with some real-world connective tissue behind it. Carolyn Kissane, associate dean at NYU's Center for Global Affairs, has joined as an independent director. The appointment is not a product launch, a contract, or revenue. It is a governance move. Still, in a business trying to weld...

Continue Reading
Oatly’s $4.13 Tender Offer Is a Legal Detour, Not a Sale

Updated Category News Views 25

A $4.13 cash offer trading against a $7.17 close is the sort of thing that makes investors squint hard, and Verlinvest is practically waving a flag telling them why. This is not a conventional attempt to buy Oatly Group AB. It is a technical tender offer built to satisfy Swedish takeover rules while Verlinvest buys out its joint-venture partner’s interest in Oatly’s...

Continue Reading
Ampace Targets AI Data Centre UPS Safety Needs in Paris

Updated Category News Views 94

Backup power gets interesting only after the grid has disappointed everybody. At Data Centre World Paris 2026, Ampace put its attention on that ugly, split-second handoff: utility power drops, a UPS has to catch the load immediately, and nobody operating an AI data centre gets to shrug if it does not. A Narrow Job With Brutal Consequences The company showcased its PU200...

Continue Reading
CVS Puts Youth Soccer Stories on Its Store Shelves

Updated Category News Views 60

Two kids with real community ties just got a megaphone most grown-ups never receive. CVS Pharmacy has named Caroline, 9, of Holmes Beach, Florida, and Zoe, 12, of Los Angeles, as the first grand-prize winners of its Home Team Heroes youth soccer contest. Each player’s selected nonprofit soccer organization will receive a $25,000 grant, while their stories will appear on...

Continue Reading

Top 5 Most Recently Viewed Articles

Accessibility Insights: Boosting Website Rankings Effectively

Updated Category News Views 152

Accessibility Insights for Website Rankings A recent study has highlighted a compelling correlation between website accessibility and search engine ranking. Through extensive research, it has become increasingly clear that adhering to accessibility guidelines significantly impacts organic search success. This analysis underscores the importance of making websites more...

Continue Reading
CVS Health and Cigna Introduce 2025 Medicare Advantage Plans

Updated Category News Views 409

Back in 2025, CVS Health and Cigna took center stage with their new Medicare Advantage plans aimed squarely at seniors. The big pitch? Some members could enjoy $0 monthly premiums for essential prescription drugs—sounds great, right? But let's unpack that. Enrollment Window: Timing is Everything The enrollment period was set from October 15 to December 7, a critical...

Continue Reading
Kodiak AI: Pioneering the Future of Autonomous Freight Logistics

Updated Category News Views 329

Kodiak AI and Ares Acquisition Corporation II Create a New Era in Autonomous Freight Kodiak AI, Inc., a revolutionary player in the autonomous vehicle space, is ready to ignite the future of freight logistics with its recent business combination with Ares Acquisition Corporation II. This pivotal step not only solidifies Kodiak's standing as a leader in AI-driven...

Continue Reading
TRON DAO Enhances DeFi Ecosystem through Chainlink Partnership

Updated Category News Views 97

TRON DAO Joins Forces with Chainlink for DeFi Advancement The TRON network is rapidly becoming a significant player in the decentralized finance (DeFi) space, boasting one of the largest DeFi economies globally. By collaborating with Chainlink through the Chainlink Scale program, TRON DAO is set to accelerate growth and improve adoption in its ecosystem. Chainlink Data...

Continue Reading
Canton Fair Showcases Sustainable Innovations for a Greener Future

Updated Category News Views 387

Canton Fair Showcases Sustainable Innovations for a Greener Future The ongoing Canton Fair has positioned itself as a leader in promoting environmental sustainability and innovation. A remarkable 10,040 companies are showcasing their offerings, highlighting over 300,000 green and low-carbon products. This huge gathering emphasizes the importance of eco-friendly solutions...

Continue Reading